Results 281 to 290 of about 37,694,334 (372)

Collaborative research networks as a strategy to synthesize knowledge of Amazonian biodiversity. [PDF]

Proc Biol Sci
Resende BO, Juen L, Schietti J, Baccaro FB, Krempser E, Moura J, Colares L, Carvalho RL, Phillips OL, Souza G, Michelan TS, Ghidini AR, Demori A, Façanha BLB, Rosa C, Venticinque E, Bomfim F, Raseira M, Famelli S, Esquivel-Muelbert A, Kasseboehmer AC, Fares AL, Ferreira AS, Ribas CC, Castilho C, Nunes CA, Andrade DFC, Silvério D, Cunha EJR, Antunes E, Rodrigues E, Silva E, Alves-Martins F, Schmidt FA, Elias F, Carvalho FG, Vaz-de-Mello FZ, Cruz G, Palheta G, Teodoro G, Ter Steege H, Albert J, Nascimento J, Brito J, Toledo JJ, Oliveira-Junior JMB, Monteles J, Arieira J, Stropp J, Dias-Silva K, Castello L, Giacomin LL, Brasil LS, Calvão L, Vieira L, Stegmann L, Montag L, Santos MPD, Silveira M, Guerrero-Moreno MA, Nascimento N, Hamada N, Marini-Filho O, Melo P, Ferreira P, de Marco Júnior P, Maciel R, Pinheiro R, Ligeiro R, Lima R, Martins R, Koroiva R, Silva RR, Ribeiro S, Bernardi Vieira T, Tagliacollo VA, Ferreira VRS, Beiroz W, Kuikuro Y, Machado França F.   +79 more
europepmc   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Dedication: Michael P. McNulty [PDF]

, 2016
Roger Williams University Law Review Staff
core   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Interventions to enhance medication therapy safety in older patients with cognitive impairment-protocol of a systematic review with public involvement. [PDF]

BMJ Open
Jungreithmayr V, Terstegen T, Eidam A, Rastätter S, Benzinger P, Seidling HM.   +5 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Leadership in the health professions in the Philippines: a scoping review protocol. [PDF]

BMJ Open
Gabrieles M, Lipana AGR, Dicolen E.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source